Industry: Enzymatic medicine

Pneumotactix is developing a medicinal enzyme that breaks downs capsular polysaccharide, the protective shield around harmful bacterium. The process has the potential to give the body’s immune system a new advantage in fighting severe illness.

The company’s technology has demonstrated the ability to protect against lethal Streptococcus, or Strep, and their current focus is a strain of Paenibacillus. 

Pneumotactix is working to investigate the potential toxicity and immunogenicity of the enzyme and is exploring ways to optimize its production.

Company website: Pneumotactix

Back to companies